LEGEND BIOTECH CORP
NASDAQ: LEGN (Legend Biotech Corporation)
Last update: yesterday, 6:49AM18.55
-0.50 (-2.62%)
| Previous Close | 19.05 |
| Open | 18.79 |
| Volume | 2,564,212 |
| Avg. Volume (3M) | 2,845,693 |
| Market Cap | 3,588,307,968 |
| Price / Earnings (Forward) | 128.21 |
| Price / Sales | 3.12 |
| Price / Book | 3.85 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2026 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Legend Biotech Corporation | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |